$MOH
MOLINA HEALTHCARE, INC.

2021 Q4 Form 10-Q Financial Statement

#000117992921000171 Filed on October 28, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $7.409B $7.040B $5.021B
YoY Change 41.53% 40.21% 18.34%
Cost Of Revenue $6.362B $6.049B $4.098B
YoY Change 44.33% 47.61% 16.32%
Gross Profit $1.047B $991.0M $923.0M
YoY Change 26.6% 7.37% 64.53%
Gross Profit Margin 14.13% 14.08% 18.38%
Selling, General & Admin $790.0M $736.0M $608.0M
YoY Change 14.49% 21.05% 37.56%
% of Gross Profit 75.45% 74.27% 65.87%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $35.00M $32.00M $23.00M
YoY Change 45.83% 39.13% 9.52%
% of Gross Profit 3.34% 3.23% 2.49%
Operating Expenses $825.0M $768.0M $631.0M
YoY Change 15.55% 21.71% 36.29%
Operating Profit $222.0M $221.0M $289.0M
YoY Change 96.46% -23.53% 12.45%
Interest Expense -$30.00M $30.00M $27.00M
YoY Change 0.0% 11.11% 22.73%
% of Operating Profit -13.51% 13.57% 9.34%
Other Income/Expense, Net -$25.00M -$30.00M -$27.00M
YoY Change 11.11% 12.5%
Pretax Income $136.0M $191.0M $262.0M
YoY Change 166.67% -27.1% 12.45%
Income Tax $33.00M $48.00M $77.00M
% Of Pretax Income 24.26% 25.13% 29.39%
Net Earnings $103.0M $143.0M $185.0M
YoY Change 202.94% -22.7% 5.71%
Net Earnings / Revenue 1.39% 2.03% 3.68%
Basic Earnings Per Share $2.49 $3.14
Diluted Earnings Per Share $1.749M $2.46 $3.10
COMMON SHARES
Basic Shares Outstanding 58.40M shares 57.80M shares 58.70M shares
Diluted Shares Outstanding 58.50M shares 59.60M shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.640B $7.257B $4.965B
YoY Change 26.72% 46.16% 11.93%
Cash & Equivalents $4.438B $4.357B $3.196B
Short-Term Investments $3.202B $2.900B $1.769B
Other Short-Term Assets $247.0M $197.0M $213.0M
YoY Change 41.14% -7.51% 32.3%
Inventory
Prepaid Expenses
Receivables $2.177B $1.912B $1.775B
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $10.06B $9.366B $6.953B
YoY Change 27.78% 34.7% 18.31%
LONG-TERM ASSETS
Property, Plant & Equipment $396.0M $385.0M $395.0M
YoY Change -14.29% -2.53% 4.22%
Goodwill $982.0M
YoY Change 41.91%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $179.0M $128.0M $101.0M
YoY Change 50.42% 26.73% -6.48%
Total Long-Term Assets $2.145B $1.667B $928.0M
YoY Change 29.53% 79.63% 12.62%
TOTAL ASSETS
Total Short-Term Assets $10.06B $9.366B $6.953B
Total Long-Term Assets $2.145B $1.667B $928.0M
Total Assets $12.21B $11.03B $7.881B
YoY Change 28.08% 39.99% 17.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $842.0M $797.0M $566.0M
YoY Change 38.49% 40.81% 28.05%
Accrued Expenses
YoY Change
Deferred Revenue $370.0M $1.000M $61.00M
YoY Change -1.33% -98.36% -70.53%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.047B $6.070B $3.556B
YoY Change 41.93% 70.7% 7.5%
LONG-TERM LIABILITIES
Long-Term Debt $2.173B $2.130B $1.813B
YoY Change 2.16% 17.48% 46.33%
Other Long-Term Liabilities $140.0M $95.00M $85.00M
YoY Change 17.65% 11.76% -5.56%
Total Long-Term Liabilities $2.313B $2.225B $1.898B
YoY Change 2.98% 17.23% 42.81%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.047B $6.070B $3.556B
Total Long-Term Liabilities $2.313B $2.225B $1.898B
Total Liabilities $9.579B $8.515B $5.680B
YoY Change 28.82% 49.91% 16.63%
SHAREHOLDERS EQUITY
Retained Earnings $2.399B $2.296B $1.983B
YoY Change 28.98% 15.78% 19.03%
Common Stock $236.0M $205.0M $181.0M
YoY Change 18.59% 13.26% 13.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.630B $2.518B $2.201B
YoY Change
Total Liabilities & Shareholders Equity $12.21B $11.03B $7.881B
YoY Change 28.08% 39.99% 17.61%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income $103.0M $143.0M $185.0M
YoY Change 202.94% -22.7% 5.71%
Depreciation, Depletion And Amortization $35.00M $32.00M $23.00M
YoY Change 45.83% 39.13% 9.52%
Cash From Operating Activities $597.0M $461.0M -$158.0M
YoY Change -54.04% -391.77% -165.29%
INVESTING ACTIVITIES
Capital Expenditures -$21.00M -$27.00M -$19.00M
YoY Change 110.0% 42.11% 90.0%
Acquisitions
YoY Change
Other Investing Activities -$526.0M -$671.0M $79.00M
YoY Change 7.79% -949.37% -75.54%
Cash From Investing Activities -$547.0M -$698.0M $60.00M
YoY Change 9.84% -1263.33% -80.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 21.00M -4.000M -2.000M
YoY Change -86.54% 100.0% -98.65%
NET CHANGE
Cash From Operating Activities 597.0M 461.0M -158.0M
Cash From Investing Activities -547.0M -698.0M 60.00M
Cash From Financing Activities 21.00M -4.000M -2.000M
Net Change In Cash 71.00M -241.0M -100.0M
YoY Change -92.58% 141.0% -124.57%
FREE CASH FLOW
Cash From Operating Activities $597.0M $461.0M -$158.0M
Capital Expenditures -$21.00M -$27.00M -$19.00M
Free Cash Flow $618.0M $488.0M -$139.0M
YoY Change -52.79% -451.08% -155.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001179929
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-31719
dei Entity Registrant Name
EntityRegistrantName
MOLINA HEALTHCARE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-4204626
dei Entity Address Address Line1
EntityAddressAddressLine1
200 Oceangate
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Long Beach,
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90802
dei City Area Code
CityAreaCode
562
dei Local Phone Number
LocalPhoneNumber
435-3666
dei Security12b Title
Security12bTitle
Common Stock, $0.001 Par Value
dei Trading Symbol
TradingSymbol
MOH
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58400000 shares
CY2021Q3 us-gaap Premiums Earned Net
PremiumsEarnedNet
6800000000 USD
CY2020Q3 us-gaap Premiums Earned Net
PremiumsEarnedNet
4768000000 USD
us-gaap Premiums Earned Net
PremiumsEarnedNet
19689000000 USD
us-gaap Premiums Earned Net
PremiumsEarnedNet
13444000000 USD
CY2021Q3 moh Health Care Organization Premium Tax Revenue
HealthCareOrganizationPremiumTaxRevenue
204000000 USD
CY2020Q3 moh Health Care Organization Premium Tax Revenue
HealthCareOrganizationPremiumTaxRevenue
170000000 USD
moh Health Care Organization Premium Tax Revenue
HealthCareOrganizationPremiumTaxRevenue
576000000 USD
moh Health Care Organization Premium Tax Revenue
HealthCareOrganizationPremiumTaxRevenue
477000000 USD
CY2021Q3 moh Health Care Organization Insurer Fee Revenue
HealthCareOrganizationInsurerFeeRevenue
0 USD
CY2020Q3 moh Health Care Organization Insurer Fee Revenue
HealthCareOrganizationInsurerFeeRevenue
69000000 USD
moh Health Care Organization Insurer Fee Revenue
HealthCareOrganizationInsurerFeeRevenue
0 USD
moh Health Care Organization Insurer Fee Revenue
HealthCareOrganizationInsurerFeeRevenue
206000000 USD
CY2021Q3 us-gaap Net Investment Income
NetInvestmentIncome
20000000 USD
CY2020Q3 us-gaap Net Investment Income
NetInvestmentIncome
10000000 USD
us-gaap Net Investment Income
NetInvestmentIncome
39000000 USD
us-gaap Net Investment Income
NetInvestmentIncome
48000000 USD
CY2021Q3 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
16000000 USD
CY2020Q3 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
4000000 USD
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
58000000 USD
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
13000000 USD
CY2021Q3 us-gaap Revenues
Revenues
7040000000 USD
CY2020Q3 us-gaap Revenues
Revenues
5021000000 USD
us-gaap Revenues
Revenues
20362000000 USD
us-gaap Revenues
Revenues
14188000000 USD
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6049000000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4098000000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
17342000000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11412000000 USD
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
532000000 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
368000000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1489000000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1030000000 USD
CY2021Q3 moh Premium Tax Expenses
PremiumTaxExpenses
204000000 USD
CY2020Q3 moh Premium Tax Expenses
PremiumTaxExpenses
170000000 USD
moh Premium Tax Expenses
PremiumTaxExpenses
576000000 USD
moh Premium Tax Expenses
PremiumTaxExpenses
477000000 USD
CY2021Q3 moh Health Care Organization Insurer Fee Expense
HealthCareOrganizationInsurerFeeExpense
0 USD
CY2020Q3 moh Health Care Organization Insurer Fee Expense
HealthCareOrganizationInsurerFeeExpense
70000000 USD
moh Health Care Organization Insurer Fee Expense
HealthCareOrganizationInsurerFeeExpense
0 USD
moh Health Care Organization Insurer Fee Expense
HealthCareOrganizationInsurerFeeExpense
209000000 USD
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
32000000 USD
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
23000000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
96000000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
64000000 USD
CY2021Q3 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
2000000 USD
CY2020Q3 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
3000000 USD
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
30000000 USD
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
9000000 USD
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
6819000000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
4732000000 USD
us-gaap Costs And Expenses
CostsAndExpenses
19533000000 USD
us-gaap Costs And Expenses
CostsAndExpenses
13201000000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
221000000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
289000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
829000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
987000000 USD
CY2021Q3 us-gaap Interest Expense
InterestExpense
30000000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
27000000 USD
us-gaap Interest Expense
InterestExpense
90000000 USD
us-gaap Interest Expense
InterestExpense
72000000 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000000 USD
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-30000000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-27000000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-90000000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-77000000 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
191000000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
262000000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
739000000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
910000000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
48000000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
9.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
10.80
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.46
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
9.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
10.65
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
77000000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
183000000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
271000000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
143000000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
185000000 USD
us-gaap Net Income Loss
NetIncomeLoss
556000000 USD
us-gaap Net Income Loss
NetIncomeLoss
639000000 USD
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.49
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.14
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
143000000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
185000000 USD
us-gaap Net Income Loss
NetIncomeLoss
556000000 USD
us-gaap Net Income Loss
NetIncomeLoss
639000000 USD
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-13000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
6000000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-27000000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
43000000 USD
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-4000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
1000000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-7000000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
10000000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-9000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
5000000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-20000000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
33000000 USD
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
134000000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
190000000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
536000000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
672000000 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4357000000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4154000000 USD
CY2021Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
2900000000 USD
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1875000000 USD
CY2021Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
1912000000 USD
CY2020Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
1672000000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
197000000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
175000000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
9366000000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
7876000000 USD
CY2021Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
385000000 USD
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
391000000 USD
CY2021Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
915000000 USD
CY2020Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
941000000 USD
CY2021Q3 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
156000000 USD
CY2020Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
136000000 USD
CY2021Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
83000000 USD
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
69000000 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
128000000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
119000000 USD
CY2021Q3 us-gaap Assets
Assets
11033000000 USD
CY2020Q4 us-gaap Assets
Assets
9532000000 USD
CY2021Q3 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
3191000000 USD
CY2020Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
2696000000 USD
CY2021Q3 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
2081000000 USD
CY2020Q4 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
1253000000 USD
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
797000000 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
641000000 USD
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1000000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
375000000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6070000000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4965000000 USD
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2130000000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2127000000 USD
CY2021Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
220000000 USD
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
225000000 USD
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
95000000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
119000000 USD
CY2021Q3 us-gaap Liabilities
Liabilities
8515000000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
7436000000 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58000000 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59000000 shares
CY2021Q3 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
0 USD
CY2020Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
0 USD
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
205000000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
199000000 USD
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
17000000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
37000000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2296000000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1860000000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
2518000000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
2096000000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11033000000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9532000000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2096000000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
228000000 USD
CY2021Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
122000000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-11000000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-27000000 USD
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2164000000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
185000000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
21000000 USD
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2370000000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
143000000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-9000000 USD
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
14000000 USD
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2518000000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1960000000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
178000000 USD
CY2020Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
446000000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-30000000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-19000000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4000000 USD
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1647000000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
276000000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
47000000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
26000000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1996000000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
185000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
5000000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
15000000 USD
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2201000000 USD
us-gaap Net Income Loss
NetIncomeLoss
556000000 USD
us-gaap Net Income Loss
NetIncomeLoss
639000000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
96000000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
64000000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
8000000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
3000000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
49000000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
43000000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-5000000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
9000000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
2000000 USD
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
247000000 USD
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
369000000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
43000000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
98000000 USD
us-gaap Increase Decrease In Health Care Insurance Liabilities
IncreaseDecreaseInHealthCareInsuranceLiabilities
522000000 USD
us-gaap Increase Decrease In Health Care Insurance Liabilities
IncreaseDecreaseInHealthCareInsuranceLiabilities
431000000 USD
moh Increase Decrease In Medical Premium Liability Due To Agency
IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
810000000 USD
moh Increase Decrease In Medical Premium Liability Due To Agency
IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
-24000000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
129000000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
63000000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-374000000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-188000000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
23000000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
34000000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1522000000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
599000000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
2018000000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
670000000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
965000000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
891000000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
56000000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
64000000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
62000000 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-3000000 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-3000000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1106000000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
98000000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
128000000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
453000000 USD
moh Common Stock Withheld To Settle Employee Tax Obligations
CommonStockWithheldToSettleEmployeeTaxObligations
52000000 USD
moh Common Stock Withheld To Settle Employee Tax Obligations
CommonStockWithheldToSettleEmployeeTaxObligations
8000000 USD
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
20000000 USD
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
0 USD
us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
0 USD
us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
789000000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2508000000 USD
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0 USD
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
600000000 USD
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0 USD
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
380000000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-4000000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-47000000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-204000000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
61000000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
212000000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
758000000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4223000000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4435000000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3266000000 USD
CY2021Q3 moh Health Plan Contract Term
HealthPlanContractTerm
P4Y
CY2021Q3 moh Health Plan Extension Option Period
HealthPlanExtensionOptionPeriod
P2Y
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3196000000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Principal areas requiring the use of estimates include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of medical claims and benefits payable;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contractual provisions that may limit revenue recognition based upon the costs incurred or the profits realized under a specific contract;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Quality incentives that allow us to recognize incremental revenue if certain quality standards are met;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Settlements under risk- or savings-sharing programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Purchase price allocations relating to business combinations, including the determination of contingent consideration;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The assessment of long-lived and intangible assets, and goodwill for impairment;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of reserves for potential absorption of claims unpaid by insolvent providers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of reserves for the outcome of litigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of valuation allowances for deferred tax assets; and</span></div>•The determination of unrecognized tax benefits.
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4357000000 USD
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
78000000 USD
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
70000000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4435000000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3266000000 USD
CY2021Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
1912000000 USD
CY2020Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
1672000000 USD
CY2020Q4 moh Amounts Due To Government Agencies Risk Adjustment And Part D Risk Sharing
AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing
45000000 USD
CY2021Q3 moh Amounts Due To Government Agencies Medicare Medical Loss Ratio And Profit Sharing Threshold
AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold
82000000 USD
CY2021Q3 moh Medical Premiums Liability Medical Care Costs Threshold
MedicalPremiumsLiabilityMedicalCareCostsThreshold
852000000 USD
CY2020Q4 moh Medical Premiums Liability Medical Care Costs Threshold
MedicalPremiumsLiabilityMedicalCareCostsThreshold
513000000 USD
CY2021Q3 moh Amounts Due To Government Agencies Medicaid Other
AmountsDueToGovernmentAgenciesMedicaidOther
249000000 USD
CY2020Q4 moh Amounts Due To Government Agencies Medicaid Other
AmountsDueToGovernmentAgenciesMedicaidOther
76000000 USD
CY2021Q3 moh Amounts Due To Government Agencies Risk Adjustment And Part D Risk Sharing
AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing
87000000 USD
CY2020Q4 moh Amounts Due To Government Agencies Medicare Medical Loss Ratio And Profit Sharing Threshold
AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold
62000000 USD
CY2021Q3 moh Other Medicare Program
OtherMedicareProgram
41000000 USD
CY2020Q4 moh Other Medicare Program
OtherMedicareProgram
30000000 USD
CY2021Q3 moh Amounts Dueto Government Agencies Risk Adjustment
AmountsDuetoGovernmentAgenciesRiskAdjustment
691000000 USD
CY2020Q4 moh Amounts Dueto Government Agencies Risk Adjustment
AmountsDuetoGovernmentAgenciesRiskAdjustment
326000000 USD
CY2021Q3 moh Amounts Due To Government Agencies Marketplace Medical Loss Ratio Threshold
AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold
30000000 USD
CY2020Q4 moh Amounts Due To Government Agencies Marketplace Medical Loss Ratio Threshold
AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold
37000000 USD
CY2021Q3 moh Amounts Dueto Government Agencies Other
AmountsDuetoGovernmentAgenciesOther
49000000 USD
CY2020Q4 moh Amounts Dueto Government Agencies Other
AmountsDuetoGovernmentAgenciesOther
21000000 USD
CY2021Q3 moh Amounts Due To Government Agencies Business Combination
AmountsDueToGovernmentAgenciesBusinessCombination
0 USD
CY2020Q4 moh Amounts Due To Government Agencies Business Combination
AmountsDueToGovernmentAgenciesBusinessCombination
143000000 USD
CY2021Q3 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
2081000000 USD
CY2020Q4 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
1253000000 USD
CY2021Q3 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable
691000000 USD
CY2021Q3 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable
29000000 USD
CY2021Q3 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Net Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable
662000000 USD
CY2021Q3 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable Payable Current Year
AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear
-660000000 USD
CY2020Q3 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Net Payable Receivable Prior Years
AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears
-2000000 USD
CY2020Q4 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable
326000000 USD
CY2020Q4 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable
20000000 USD
CY2020Q4 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Net Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable
306000000 USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 10 years, or less than 10 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and the local governments of the states in which our health plan subsidiaries operate.</span></div>
moh Investments Maturity Period
InvestmentsMaturityPeriod
P10Y
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
143000000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
185000000 USD
us-gaap Net Income Loss
NetIncomeLoss
556000000 USD
us-gaap Net Income Loss
NetIncomeLoss
639000000 USD
CY2021Q2 us-gaap Shares Outstanding
SharesOutstanding
57800000 shares
CY2020Q2 us-gaap Shares Outstanding
SharesOutstanding
58700000 shares
CY2020Q4 us-gaap Shares Outstanding
SharesOutstanding
58000000.0 shares
CY2019Q4 us-gaap Shares Outstanding
SharesOutstanding
61900000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
500000 shares
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
2800000 shares
CY2021Q3 moh Weighted Average Numberof Shares Share Based Compensation
WeightedAverageNumberofSharesShareBasedCompensation
0 shares
CY2020Q3 moh Weighted Average Numberof Shares Share Based Compensation
WeightedAverageNumberofSharesShareBasedCompensation
0 shares
moh Weighted Average Numberof Shares Share Based Compensation
WeightedAverageNumberofSharesShareBasedCompensation
300000 shares
moh Weighted Average Numberof Shares Share Based Compensation
WeightedAverageNumberofSharesShareBasedCompensation
100000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57800000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58700000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57800000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59200000 shares
CY2021Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
700000 shares
CY2020Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
900000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
700000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
800000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58500000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59600000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58500000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60000000.0 shares
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.49
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
9.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
10.80
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.46
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
9.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
10.65
CY2021Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
2900000000 USD
CY2021Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
26000000 USD
CY2021Q3 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
2900000000 USD
CY2020Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
1826000000 USD
CY2021Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
26000000 USD
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
1875000000 USD
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
46000000 USD
CY2020Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
46000000 USD
us-gaap Gain Loss On Fair Value Hedges Recognized In Earnings
GainLossOnFairValueHedgesRecognizedInEarnings
-3000000 USD
CY2021Q3 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
2878000000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
25000000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
50000000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000000 USD
CY2020Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
1875000000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
555000000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
557000000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
1530000000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
1546000000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
296000000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
298000000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities After Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
497000000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
499000000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
2878000000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue
2900000000 USD
CY2021Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
6000000 USD
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
7000000 USD
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
6000000 USD
CY2021Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
779000000 USD
CY2021Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
3000000 USD
CY2021Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
3000000 USD
CY2021Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
268 position
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
77000000 USD
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
1000000 USD
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
21 position
CY2021Q3 us-gaap Debt Securities Held To Maturity Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesHeldToMaturityExcludingAccruedInterestBeforeAllowanceForCreditLoss
156000000 USD
CY2021Q3 us-gaap Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
148000000 USD
CY2021Q3 us-gaap Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
8000000 USD
us-gaap Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense
ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of our medical claims and benefits payable as of the dates indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fee-for-service claims incurred but not paid (“IBNP”)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,647 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">528 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Magellan Complete Care acquisition opening balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,191 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,696 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div>
CY2021Q3 moh Liabilityfor Unpaid Claimsand Claims Adjustment Expense Incurredbut Not Paid Ibnp Feeforservice Claims Amount
LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
2246000000 USD
CY2020Q4 moh Liabilityfor Unpaid Claimsand Claims Adjustment Expense Incurredbut Not Paid Ibnp Feeforservice Claims Amount
LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
1647000000 USD
CY2021Q3 moh Pharmacy Claims Payable
PharmacyClaimsPayable
209000000 USD
CY2020Q4 moh Pharmacy Claims Payable
PharmacyClaimsPayable
157000000 USD
CY2021Q3 moh Capitation Claims Payable
CapitationClaimsPayable
86000000 USD
CY2020Q4 moh Capitation Claims Payable
CapitationClaimsPayable
70000000 USD
CY2021Q3 moh Other Claims Payable
OtherClaimsPayable
650000000 USD
CY2020Q4 moh Other Claims Payable
OtherClaimsPayable
528000000 USD
CY2021Q3 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
3191000000 USD
CY2020Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
2696000000 USD
CY2021Q3 moh Medical Claims And Benefits Payable
MedicalClaimsAndBenefitsPayable
301000000 USD
CY2020Q4 moh Medical Claims And Benefits Payable
MedicalClaimsAndBenefitsPayable
235000000 USD
CY2020Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
2696000000 USD
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
17558000000 USD
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-216000000 USD
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
17342000000 USD
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
14880000000 USD
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
2008000000 USD
us-gaap Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
16888000000 USD
moh Change In Acquired Balances
ChangeInAcquiredBalances
-27000000 USD
moh Medical Claims And Benefits Payable Adjustments Change In Provider
MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
68000000 USD
CY2021Q3 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
3191000000 USD
CY2019Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
1854000000 USD
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
11478000000 USD
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-66000000 USD
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
11412000000 USD
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
9500000000 USD
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
1527000000 USD
us-gaap Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
11027000000 USD
moh Medical Claims And Benefits Payable Adjustments Change In Provider
MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
50000000 USD
CY2020Q3 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
2289000000 USD
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-216000000 USD
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-66000000 USD
CY2021Q3 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
20000000 USD
CY2020Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
23000000 USD
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2130000000 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2127000000 USD
CY2021Q3 us-gaap Revenues
Revenues
7040000000 USD
CY2020Q3 us-gaap Revenues
Revenues
5021000000 USD
us-gaap Revenues
Revenues
20362000000 USD
us-gaap Revenues
Revenues
14188000000 USD
CY2021Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
915000000 USD
CY2020Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
941000000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
221000000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
289000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
829000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
987000000 USD
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-30000000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-27000000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-90000000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-77000000 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
191000000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
262000000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
739000000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
910000000 USD

Files In Submission

Name View Source Status
0001179929-21-000171-index-headers.html Edgar Link pending
0001179929-21-000171-index.html Edgar Link pending
0001179929-21-000171.txt Edgar Link pending
0001179929-21-000171-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
moh-20210930.htm Edgar Link pending
moh-20210930.xsd Edgar Link pending
moh-20210930_cal.xml Edgar Link unprocessable
moh-20210930_def.xml Edgar Link unprocessable
moh-20210930_g1.jpg Edgar Link pending
moh-20210930_htm.xml Edgar Link completed
moh-20210930_lab.xml Edgar Link unprocessable
moh-20210930_pre.xml Edgar Link unprocessable
moh3q21_ex311.htm Edgar Link pending
moh3q21_ex312.htm Edgar Link pending
moh3q21_ex321.htm Edgar Link pending
moh3q21_ex322.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending